Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Nemaline myopathies: a current view.

Sewry CA, Laitila JM, Wallgren-Pettersson C.

J Muscle Res Cell Motil. 2019 Jun 21. doi: 10.1007/s10974-019-09519-9. [Epub ahead of print]

PMID:
31228046
2.

Liquid chromatography-tandem mass spectrometry reveals detailed chromatographic fingerprints of anthocyanins and anthocyanin adducts in red wine.

Laitila JE, Suvanto J, Salminen JP.

Food Chem. 2019 Oct 1;294:138-151. doi: 10.1016/j.foodchem.2019.02.136. Epub 2019 Apr 29.

PMID:
31126446
3.

Cullin-3 dependent deregulation of ACTN1 represents a new pathogenic mechanism in nemaline myopathy.

Blondelle J, Tallapaka K, Seto JT, Ghassemian M, Clark M, Laitila JM, Bournazos A, Singer JD, Lange S.

JCI Insight. 2019 Apr 16;5. pii: 125665. doi: 10.1172/jci.insight.125665.

4.

Dominantly inherited distal nemaline/cap myopathy caused by a large deletion in the nebulin gene.

Kiiski KJ, Lehtokari VL, Vihola AK, Laitila JM, Huovinen S, Sagath LJ, Evilä AE, Paetau AE, Sewry CA, Hackman PB, Pelin KB, Wallgren-Pettersson C, Udd B.

Neuromuscul Disord. 2019 Feb;29(2):97-107. doi: 10.1016/j.nmd.2018.12.007. Epub 2018 Dec 20.

PMID:
30679003
5.

Two alternatively-spliced human nebulin isoforms with either exon 143 or exon 144 and their developmental regulation.

Lam LT, Holt I, Laitila J, Hanif M, Pelin K, Wallgren-Pettersson C, Sewry CA, Morris GE.

Sci Rep. 2018 Oct 24;8(1):15728. doi: 10.1038/s41598-018-33281-6.

6.

A nebulin super-repeat panel reveals stronger actin binding toward the ends of the super-repeat region.

Laitila J, Lehtonen J, Lehtokari VL, Sagath L, Wallgren-Pettersson C, Grönholm M, Pelin K.

Muscle Nerve. 2019 Jan;59(1):116-121. doi: 10.1002/mus.26350. Epub 2018 Nov 13.

PMID:
30265400
7.

Voriconazole greatly increases the exposure to oral buprenorphine.

Fihlman M, Hemmilä T, Hagelberg NM, Backman JT, Laitila J, Laine K, Neuvonen PJ, Olkkola KT, Saari TI.

Eur J Clin Pharmacol. 2018 Dec;74(12):1615-1622. doi: 10.1007/s00228-018-2548-8. Epub 2018 Aug 30.

PMID:
30167757
8.

Community structure of insect herbivores is driven by conservatism, escalation and divergence of defensive traits in Ficus.

Volf M, Segar ST, Miller SE, Isua B, Sisol M, Aubona G, Šimek P, Moos M, Laitila J, Kim J, Zima J Jr, Rota J, Weiblen GD, Wossa S, Salminen JP, Basset Y, Novotny V.

Ecol Lett. 2018 Jan;21(1):83-92. doi: 10.1111/ele.12875. Epub 2017 Nov 15.

PMID:
29143434
9.

Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects.

Hagelberg NM, Fihlman M, Hemmilä T, Backman JT, Laitila J, Neuvonen PJ, Laine K, Olkkola KT, Saari TI.

Pharmacol Res Perspect. 2016 Nov 3;4(6):e00271. doi: 10.1002/prp2.271. eCollection 2016 Dec.

10.

Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.

Fihlman M, Hemmilä T, Hagelberg NM, Kuusniemi K, Backman JT, Laitila J, Laine K, Neuvonen PJ, Olkkola KT, Saari TI.

Eur J Clin Pharmacol. 2016 Nov;72(11):1363-1371. Epub 2016 Aug 10.

PMID:
27510521
11.

Do Diuretics have Antinociceptive Actions: Studies of Spironolactone, Eplerenone, Furosemide and Chlorothiazide, Individually and with Oxycodone and Morphine.

Jokinen V, Lilius T, Laitila J, Niemi M, Kambur O, Kalso E, Rauhala P.

Basic Clin Pharmacol Toxicol. 2017 Jan;120(1):38-45. doi: 10.1111/bcpt.12634. Epub 2016 Jul 21.

12.

FORUM: Indirect leakage leads to a failure of avoided loss biodiversity offsetting.

Moilanen A, Laitila J.

J Appl Ecol. 2016 Feb;53(1):106-111. Epub 2015 Nov 27.

13.

A recurrent copy number variation of the NEB triplicate region: only revealed by the targeted nemaline myopathy CGH array.

Kiiski K, Lehtokari VL, Löytynoja A, Ahlstén L, Laitila J, Wallgren-Pettersson C, Pelin K.

Eur J Hum Genet. 2016 Apr;24(4):574-80. doi: 10.1038/ejhg.2015.166. Epub 2015 Jul 22.

14.

Pregabalin enhances the antinociceptive effect of oxycodone and morphine in thermal models of nociception in the rat without any pharmacokinetic interactions.

Jokinen V, Lilius TO, Laitila J, Niemi M, Rauhala PV, Kalso EA.

Eur J Pain. 2016 Feb;20(2):297-306. doi: 10.1002/ejp.728. Epub 2015 May 29.

PMID:
26031840
15.

A method for calculating minimum biodiversity offset multipliers accounting for time discounting, additionality and permanence.

Laitila J, Moilanen A, Pouzols FM.

Methods Ecol Evol. 2014 Nov;5(11):1247-1254. Epub 2014 Nov 29.

16.

Identification of policies for a sustainable legal trade in rhinoceros horn based on population projection and socioeconomic models.

Di Minin E, Laitila J, Montesino-Pouzols F, Leader-Williams N, Slotow R, Goodman PS, Conway AJ, Moilanen A.

Conserv Biol. 2015 Apr;29(2):545-55. doi: 10.1111/cobi.12412. Epub 2014 Oct 20.

17.

Nebulin interactions with actin and tropomyosin are altered by disease-causing mutations.

Marttila M, Hanif M, Lemola E, Nowak KJ, Laitila J, Grönholm M, Wallgren-Pettersson C, Pelin K.

Skelet Muscle. 2014 Aug 1;4:15. doi: 10.1186/2044-5040-4-15. eCollection 2014.

18.

Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.

Filppula AM, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT.

Drug Metab Dispos. 2013 Jan;41(1):50-9. doi: 10.1124/dmd.112.048017. Epub 2012 Oct 1.

PMID:
23028140
19.

Expression of multiple nebulin isoforms in human skeletal muscle and brain.

Laitila J, Hanif M, Paetau A, Hujanen S, Keto J, Somervuo P, Huovinen S, Udd B, Wallgren-Pettersson C, Auvinen P, Hackman P, Pelin K.

Muscle Nerve. 2012 Nov;46(5):730-7. doi: 10.1002/mus.23380. Epub 2012 Aug 31.

PMID:
22941678
20.

Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.

Karonen T, Laitila J, Niemi M, Neuvonen PJ, Backman JT.

Eur J Clin Pharmacol. 2012 May;68(5):681-8. doi: 10.1007/s00228-011-1158-5. Epub 2011 Nov 23.

PMID:
22108774
21.

Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.

Filppula AM, Laitila J, Neuvonen PJ, Backman JT.

Br J Pharmacol. 2012 Apr;165(8):2787-98. doi: 10.1111/j.1476-5381.2011.01732.x.

22.

Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations.

Filppula AM, Laitila J, Neuvonen PJ, Backman JT.

Drug Metab Dispos. 2011 May;39(5):904-11. doi: 10.1124/dmd.110.037689. Epub 2011 Feb 2.

PMID:
21289076
23.

Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.

Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2010 Aug;88(2):223-30. doi: 10.1038/clpt.2010.73. Epub 2010 Jun 30.

PMID:
20592724
24.

High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma.

Xiang X, Han Y, Neuvonen M, Laitila J, Neuvonen PJ, Niemi M.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jan 1;878(1):51-60. doi: 10.1016/j.jchromb.2009.11.019.

PMID:
19945922
25.

Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.

Xiang X, Han Y, Neuvonen M, Pasanen MK, Kalliokoski A, Backman JT, Laitila J, Neuvonen PJ, Niemi M.

Pharmacogenet Genomics. 2009 Jun;19(6):447-57. doi: 10.1097/FPC.0b013e32832bcf7b.

PMID:
19387419
26.

The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.

Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2008 Sep;84(3):403-11. doi: 10.1038/clpt.2008.34. Epub 2008 Mar 26.

PMID:
18388877
27.

Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.

Backman JT, Karjalainen MJ, Neuvonen M, Laitila J, Neuvonen PJ.

Br J Clin Pharmacol. 2006 Sep;62(3):345-57.

28.

Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.

Jaakkola T, Laitila J, Neuvonen PJ, Backman JT.

Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.

29.

Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.

Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT.

Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.

30.

Effect of rifampicin on the pharmacokinetics of pioglitazone.

Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ.

Br J Clin Pharmacol. 2006 Jan;61(1):70-8.

31.
32.

Cyclosporine markedly raises the plasma concentrations of repaglinide.

Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2005 Oct;78(4):388-99.

PMID:
16198658
33.

Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.

Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT.

Basic Clin Pharmacol Toxicol. 2005 Oct;97(4):249-56.

34.

Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.

Tornio A, Pasanen MK, Laitila J, Neuvonen PJ, Backman JT.

Basic Clin Pharmacol Toxicol. 2005 Aug;97(2):104-8.

35.

Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.

Kajosaari LI, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ.

Br J Clin Pharmacol. 2004 Oct;58(4):390-6.

36.

Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro.

Granfors MT, Backman JT, Laitila J, Neuvonen PJ.

Br J Clin Pharmacol. 2004 Mar;57(3):349-53.

37.

Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients.

Raaska K, Raitasuo V, Laitila J, Neuvonen PJ.

Basic Clin Pharmacol Toxicol. 2004 Jan;94(1):13-8.

38.

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone.

Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ.

Diabetologia. 2003 Oct;46(10):1319-23. Epub 2003 Jul 29.

PMID:
12898007
39.

Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol.

Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ.

Clin Pharmacol Ther. 2003 Mar;73(3):192-8.

PMID:
12621384
40.

Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.

Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ.

Drug Metab Dispos. 2002 Jun;30(6):631-5.

PMID:
12019187
41.

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate.

Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ.

Clin Pharmacol Ther. 2001 May;69(5):340-5.

PMID:
11372002
42.

Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.

Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivistö KT.

Clin Pharmacol Ther. 2001 Apr;69(4):194-200.

PMID:
11309547
43.

Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.

Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ.

Clin Pharmacol Ther. 2000 Dec;68(6):592-7.

PMID:
11180018
44.

Pharmacokinetics of intravenous N-acetylcysteine in pre-term new-born infants.

Ahola T, Fellman V, Laaksonen R, Laitila J, Lapatto R, Neuvonen PJ, Raivio KO.

Eur J Clin Pharmacol. 1999 Nov;55(9):645-50.

PMID:
10638393
45.

Determination of buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP) in human plasma by capillary gas chromatography.

Kivistö KT, Laitila J, Mårtensson K, Neuvonen PJ.

Ther Drug Monit. 1999 Jun;21(3):317-21.

PMID:
10365644
46.

The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone.

Lamberg TS, Kivistö KT, Laitila J, Mårtensson K, Neuvonen PJ.

Eur J Clin Pharmacol. 1998 Nov-Dec;54(9-10):761-6.

PMID:
9923581
47.

Serum and muscle tissue ubiquinone levels in healthy subjects.

Laaksonen R, Riihimäki A, Laitila J, Mårtensson K, Tikkanen MJ, Himberg JJ.

J Lab Clin Med. 1995 Apr;125(4):517-21.

PMID:
7706908

Supplemental Content

Loading ...
Support Center